I
Iván Ferraz-Amaro
Researcher at Hospital Universitario de Canarias
Publications - 131
Citations - 2144
Iván Ferraz-Amaro is an academic researcher from Hospital Universitario de Canarias. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 91 publications receiving 1694 citations. Previous affiliations of Iván Ferraz-Amaro include University of Cantabria.
Papers
More filters
Journal ArticleDOI
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
I. Sadaf Farooqi,Teresia Wangensteen,Stephan C. Collins,Wendy Kimber,Giuseppe Matarese,Julia M. Keogh,Emma Lank,Bill Bottomley,Judith López-Fernández,Iván Ferraz-Amaro,Mehul T. Dattani,Oya Ercan,Anne Grethe Myhre,Lars Retterstøl,Richard Stanhope,J. A. Edge,Sheila A. McKenzie,Nader Lessan,Maryam Ghodsi,Veronica De Rosa,Francesco Perna,Silvia Fontana,Inês Barroso,Dag E. Undlien,Stephen O'Rahilly +24 more
TL;DR: The prevalence of pathogenic LEPR mutations in a cohort of subjects with severe, early-onset obesity was 3%.
Journal ArticleDOI
Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers.
Raquel López-Mejías,Santos Castañeda,Carlos González-Juanatey,Alfonso Corrales,Iván Ferraz-Amaro,Fernanda Genre,Sara Remuzgo-Martínez,Luis Rodriguez-Rodriguez,Ricardo Blanco,Javier Llorca,Javier Martín,Miguel A. González-Gay,Miguel A. González-Gay +12 more
TL;DR: In this article, a review of the current knowledge on these potential markers, especially focused on new genetic and serological biomarkers is shown in this review, and a new genetic component is revealed the relevance of a genetic component in the development of CV disease in RA patients.
Journal ArticleDOI
Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
Raimon Sanmartí,Susana García-Rodríguez,José María Álvaro-Gracia,José Luis Andreu,Alejandro Balsa,Rafael Cáliz,Antonio Fernández-Nebro,Iván Ferraz-Amaro,Juan J. Gomez-Reino,Isidoro González-Álvaro,Emilio Martín-Mola,Víctor M. Martínez-Taboada,Ana M. Ortiz,Jesús Tornero,Sara Marsal,José Vicente Moreno-Muelas +15 more
TL;DR: Se revisan las indicaciones y matizaciones del uso de terapias biologicas y cual debe ser la evaluacion previa y the vigilancia del paciente with estos farmacos.
Journal ArticleDOI
Metabolic Syndrome in Rheumatoid Arthritis
Iván Ferraz-Amaro,Carlos González-Juanatey,Raquel López-Mejías,Leyre Riancho-Zarrabeitia,Miguel A. González-Gay +4 more
TL;DR: Biologic therapies, such as TNF-α antagonists, that block proinflammatory cytokines have beneficial effects on the insulin resistance that is often observed in patients with RA.
Journal ArticleDOI
Omentin: a biomarker of cardiovascular risk in individuals with axial spondyloarthritis.
Fernanda Genre,Javier Rueda-Gotor,Sara Remuzgo-Martínez,Verónica Pulito-Cueto,Alfonso Corrales,Verónica Mijares,Leticia Lera-Gómez,Virginia Portilla,R. Expósito,Cristina Mata,Ricardo Blanco,Javier Llorca,Vanesa Hernández-Hernández,Esther Vicente,Cristina Fernández-Carballido,María Paz Martínez-Vidal,David Castro-Corredor,Joaquín Anino-Fernández,Carlos Rodríguez-Lozano,Oreste Gualillo,Juan Carlos Quevedo-Abeledo,Santos Castañeda,Iván Ferraz-Amaro,Raquel López-Mejías,Miguel A. González-Gay +24 more
TL;DR: Low omentin serum levels were associated with CV risk factors in axSpA and rs12409609 minor allele may be downregulating the expression of omentIn, and data support a role of oMENTin as a CV risk biomarker in ax SpA.